S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
Free Trial
NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free PRAN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.97
▼
$2.16
50-Day Range
$0.95
▼
$2.06
52-Week Range
$1.09
▼
$2.91
Volume
26,692 shs
Average Volume
130,956 shs
Market Capitalization
$19.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
PRAN stock logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

PRAN Stock News Headlines

April 18, 2024 | finance.yahoo.com
Kazia Therapeutics Limited (KZIA)
December 21, 2023 | nasdaq.com
Alterity Therapeutics Says Phillip Hains To Replace Kathryn Andrews As CFO
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
December 21, 2023 | markets.businessinsider.com
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
December 4, 2023 | seekingalpha.com
Alterity jumps after promising data on Parkinson's candidate
December 4, 2023 | investorplace.com
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?
October 31, 2023 | morningstar.com
Axsome Therapeutics Inc AXSM
October 8, 2023 | morningstar.com
ADRs End Higher; Orchard Therapeutics PLC Climbs 96%
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
August 23, 2023 | technews.tmcnet.com
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's
March 14, 2023 | technews.tmcnet.com
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's Disease
January 30, 2023 | marketwatch.com
Alterity: Study Shows ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal Model
September 26, 2022 | benzinga.com
Alterity Therapeutics Stock (OTC:PRNAF), Analyst Ratings, Price Targets, Predictions
September 20, 2022 | msn.com
Here's Why Alterity Therapeutics Shares Are Volatile
See More Headlines
Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
CUSIP
N/A
CIK
1131343
Web
www.pranabio.com
Phone
(139) 349-4906
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.37
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$150,000.00
Price / Sales
126.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
1.53

Miscellaneous

Outstanding Shares
8,900,000
Free Float
N/A
Market Cap
$19.05 million
Optionable
Not Optionable
Beta
1.05
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Geoffrey Paul Kempler
    Executive Chairman & Chief Executive Officer
  • Kathryn J. E. Andrews
    Chief Financial Officer
  • David A. Stamler
    Chief Medical Officer & SVP-Clinical Development
  • Phillip Allen Hains
    Secretary

Key Competitors

View All Competitors

PRAN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Alterity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA), Conatus Pharmaceuticals (CNAT), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO) and Microbot Medical (MBOT).

This page (NASDAQ:PRAN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press